Anteris Technologies advances PARADIGM trial and manufacturing scale-up in third quarter

Anteris Technologies (ASX:AVR, NASDAQ:AVR) advanced its PARADIGM Trial, expanding into new countries and gaining regulatory approvals. The company also increased manufacturing capacity. Q3 operating cash outflows were US$22.9 million, with R&D expenses at US$21.3 million.

Original reporting
Published Nov 10, 2026, 11:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 1:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Anteris Technologies advances PARADIGM trial and manufacturing scale-up in third quarter — source image
Decision brief

The 30-second read

$AVRBullishLow
01

Why it matters

The trial update reduces uncertainty around product approval and commercial timing, which can improve valuation.

02

Market read

First‑report of trial recruitment and manufacturing scale‑up provides new material information for investors.

03

What to watch

Potential regulatory delays in Europe and competition from established TAVR players.

Relevance 8/10Novelty 8/10Timing: Q3 2026 update

Background

Anteris Technologies (ASX:AVR, NASDAQ:AVR) is developing the DurAVR transcatheter heart valve and runs the PARADIGM clinical trial across multiple countries.

Company-level read

Ticker impact

$AVRBullishHigh confidence
Context

Anteris Technologies disclosed continued progress in its PARADIGM trial and expanded manufacturing capacity in Q3 2026.

Expected impact

potential upward pressure as the market prices in reduced regulatory and execution risk

Evidence & confidence

First‑report of trial recruitment and capacity expansion for a listed biotech typically moves the stock positively.

Market effects

Positive signal for the transcatheter heart‑valve sector and related device manufacturers.

May boost investor interest in Australian and US biotech listings.

Limited to cardiovascular device market; no broad macro effect.

Counterpoint

Trial progress may not translate into commercial success; execution risk remains high.

Key entities

  • Anteris Technologies

    Developer of the DurAVR transcatheter heart valve.

Related articles

$AVRMedAI 8/10

Anteris Reports Strong One-Year Results For DurAVR Heart Valve In High-Risk Aortic Stenosis Patients

Anteris Technologies (AVR) reported one-year data for its DurAVR heart valve, showing strong performance in high-risk aortic stenosis patients. Key metrics include 1% hospitalization for heart failure, 8.9 mmHg mean pressure gradient, and 96% of patients with mild or no symptoms post-treatment. The study involved 100 patients with complex conditions. Anteris stock closed at $4.99, up to $5.09 in after-hours trading.

$AVRLow

Anteris Technologies Global Corp. (AVR): Results for announcement to the market Name of entity

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Results for announcement to the market Name of entity: Anteris Technologies Global Corp. (“ATGC”) ARBN: 677 960 235 Reporting period: For the quarter ended September 30, 2026 The attached Form 10-Q Quarterly Report for the quarter ended September 30, 2026 (the “Form

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.